Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 1.00 |
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938647 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL4188358 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL4187960 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL18841185 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL3938653 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL3940495 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL3938852 | 0.85 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5191532 | 0.84 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5190328 | 0.84 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5189859 | 0.84 | HRH1 (1.00) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-7517989-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20050176708-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | HRH1 1795/4885CCR3 1/4885KCNH2 4859/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | HRH1 1870/4885CCR3 1/4885KCNH2 4861/4885 |
| US-20050176708-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | HRH1 46/4885CCR3 1/4885KCNH2 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.